B7-H3/CD276: An Emerging Cancer Immunotherapy

Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member o...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 701006
Main Authors Zhou, Wu-Tong, Jin, Wei-Lin
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 19.07.2021
Subjects
Animals
B7 Antigens
B7-H3/CD276
cancer immunotherapy
Humans
immune checkpoint
Immunology
Immunotherapy - methods
Neoplasms
tumor immunology
Tumor Microenvironment
tumor immunology
tumor microenvironment
B7-H3/CD276
cancer immunotherapy
immune checkpoint
Online AccessGet full text

Cover

Abstract Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member of the B7 family, is an attractive and promising target for cancer immunotherapy because it is overexpressed in tumor tissues while showing limited expression in normal tissues and participating in tumor microenvironment (TME) shaping and development. Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models. Herein, we present the expression and biological function of B7-H3 in distinct cancer and normal cells, as well as B7-H3-mediated signal pathways in cancer cells and B7-H3-based tumor immunotherapy strategies. This review provides a comprehensive overview that encompasses B7-H3’s role in TME to its potential as a target in cancer immunotherapy.
AbstractList Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member of the B7 family, is an attractive and promising target for cancer immunotherapy because it is overexpressed in tumor tissues while showing limited expression in normal tissues and participating in tumor microenvironment (TME) shaping and development. Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models. Herein, we present the expression and biological function of B7-H3 in distinct cancer and normal cells, as well as B7-H3-mediated signal pathways in cancer cells and B7-H3-based tumor immunotherapy strategies. This review provides a comprehensive overview that encompasses B7-H3’s role in TME to its potential as a target in cancer immunotherapy.
Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member of the B7 family, is an attractive and promising target for cancer immunotherapy because it is overexpressed in tumor tissues while showing limited expression in normal tissues and participating in tumor microenvironment (TME) shaping and development. Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models. Herein, we present the expression and biological function of B7-H3 in distinct cancer and normal cells, as well as B7-H3-mediated signal pathways in cancer cells and B7-H3-based tumor immunotherapy strategies. This review provides a comprehensive overview that encompasses B7-H3's role in TME to its potential as a target in cancer immunotherapy.Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member of the B7 family, is an attractive and promising target for cancer immunotherapy because it is overexpressed in tumor tissues while showing limited expression in normal tissues and participating in tumor microenvironment (TME) shaping and development. Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models. Herein, we present the expression and biological function of B7-H3 in distinct cancer and normal cells, as well as B7-H3-mediated signal pathways in cancer cells and B7-H3-based tumor immunotherapy strategies. This review provides a comprehensive overview that encompasses B7-H3's role in TME to its potential as a target in cancer immunotherapy.
Author Zhou, Wu-Tong
Jin, Wei-Lin
AuthorAffiliation 1 Institute of Nano Biomedicine and Engineering, Shanghai Engineering Center for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, Key Laboratory for Thin Film and Microfabrication Technology of Ministry of Education, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University , Shanghai , China
2 Institute of Cancer Neuroscience, Medical Frontier Innovation Research Center, The First Hospital of Lanzhou University, The First Clinical Medical College of Lanzhou University , Lanzhou , China
AuthorAffiliation_xml – name: 2 Institute of Cancer Neuroscience, Medical Frontier Innovation Research Center, The First Hospital of Lanzhou University, The First Clinical Medical College of Lanzhou University , Lanzhou , China
– name: 1 Institute of Nano Biomedicine and Engineering, Shanghai Engineering Center for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, Key Laboratory for Thin Film and Microfabrication Technology of Ministry of Education, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University , Shanghai , China
Author_xml – sequence: 1
  givenname: Wu-Tong
  surname: Zhou
  fullname: Zhou, Wu-Tong
– sequence: 2
  givenname: Wei-Lin
  surname: Jin
  fullname: Jin, Wei-Lin
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34349762$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1OGzEUha2KqlDgAbqpsuxmwvX_mEUlSGmJhNRNWVu2xw5GM3bwTJB4exxCEbDAC_vKPvc7Vz5f0V7KySP0DcOc0ladhDgMmzkBgucSMID4hA6wEKyhhLC9V_U-Oh7HW6iLKUop_4L2KaNMSUEOUHMum0t6svhFpDidnaXZxeDLKqbVbGGS82W2rC4pTze-mPXDEfocTD_64-fzEF3_vvi3uGyu_v5ZLs6uGscEnxrrJbdgeUdBcQNEBVBGUgBqAzjHnQUK1oqOMR4MxZ2yQRCrsGgDcGboIVruuF02t3pd4mDKg84m6qeLXFbalCm63msBDHe82oG0TAaueC0Mw6HuYJytrJ871npjB985n6Zi-jfQty8p3uhVvtctJaIFXAE_ngEl3238OOkhjs73vUk-b0ZNOG8Zx5yKKv3-2uvF5P9_VwHeCVzJ41h8eJFg0NtY9VOsehur3sVae-S7HhcnM8W8HTf2H3Q-ArUupUg
CitedBy_id crossref_primary_10_3390_cancers14246131
crossref_primary_10_3389_fimmu_2022_1088560
crossref_primary_10_1007_s00432_022_04244_2
crossref_primary_10_1186_s12885_024_11933_3
crossref_primary_10_32948_ajo_2024_09_08
crossref_primary_10_3389_fonc_2022_1031728
crossref_primary_10_1080_08820139_2022_2095285
crossref_primary_10_3390_cancers16111965
crossref_primary_10_3389_fgene_2022_1017866
crossref_primary_10_3389_fimmu_2024_1391954
crossref_primary_10_3389_fimmu_2024_1382842
crossref_primary_10_3389_fimmu_2022_1085978
crossref_primary_10_3389_fonc_2023_1146976
crossref_primary_10_1186_s12967_022_03409_4
crossref_primary_10_3390_brainsci15020212
crossref_primary_10_1002_kjm2_12891
crossref_primary_10_1021_acsptsci_4c00539
crossref_primary_10_3390_genes15121527
crossref_primary_10_3390_ijms25073976
crossref_primary_10_3390_cancers16030623
crossref_primary_10_3389_fimmu_2022_1002898
crossref_primary_10_1007_s12022_024_09822_3
crossref_primary_10_18632_aging_204869
crossref_primary_10_3390_cancers15133279
crossref_primary_10_3390_ijms232416077
crossref_primary_10_1007_s12026_024_09458_9
crossref_primary_10_1007_s00432_023_05058_6
crossref_primary_10_1186_s12935_024_03545_5
crossref_primary_10_1016_j_ccell_2023_12_018
crossref_primary_10_3390_ijms241210019
crossref_primary_10_3389_fmed_2021_793515
crossref_primary_10_3389_fonc_2022_1008770
crossref_primary_10_1038_s41598_024_64559_7
crossref_primary_10_1002_pdi3_54
crossref_primary_10_3389_fimmu_2024_1343929
crossref_primary_10_1186_s12876_024_03447_w
crossref_primary_10_1080_13102818_2024_2338432
crossref_primary_10_3748_wjg_v30_i31_3654
crossref_primary_10_3390_ijms25126383
crossref_primary_10_3390_ijms23062925
crossref_primary_10_32604_or_2024_045050
crossref_primary_10_1002_ptr_8082
crossref_primary_10_1136_jitc_2021_004424
crossref_primary_10_3389_fonc_2023_1232192
crossref_primary_10_1038_s41698_022_00323_2
crossref_primary_10_17116_onkolog20241306191
crossref_primary_10_3390_biology12020287
crossref_primary_10_1111_imcb_12723
crossref_primary_10_1186_s12951_023_02078_9
crossref_primary_10_1038_s41523_024_00618_6
crossref_primary_10_1080_2162402X_2023_2282250
crossref_primary_10_1155_2022_5939021
crossref_primary_10_3390_cancers15194722
crossref_primary_10_3389_fimmu_2022_1038096
crossref_primary_10_1038_s41598_023_40980_2
crossref_primary_10_3389_fimmu_2024_1276306
crossref_primary_10_3389_fgene_2022_989081
crossref_primary_10_3390_biomedicines11072086
crossref_primary_10_1186_s13048_024_01464_7
crossref_primary_10_3390_cancers16061202
crossref_primary_10_1186_s13073_023_01170_x
crossref_primary_10_1186_s12876_023_03045_2
crossref_primary_10_1186_s13287_025_04247_z
crossref_primary_10_1038_s41598_023_32733_y
crossref_primary_10_1158_2767_9764_CRC_23_0212
crossref_primary_10_1007_s12672_024_01171_1
crossref_primary_10_3390_cancers14194923
crossref_primary_10_1021_acschembio_2c00828
crossref_primary_10_1002_cjp2_345
crossref_primary_10_3389_fimmu_2024_1495283
crossref_primary_10_3389_fgene_2021_764184
crossref_primary_10_1186_s13045_022_01364_7
crossref_primary_10_1186_s13046_024_02949_5
crossref_primary_10_3389_fonc_2023_1091733
crossref_primary_10_3389_fimmu_2022_887471
crossref_primary_10_1016_j_clinimag_2023_109985
crossref_primary_10_1016_j_critrevonc_2024_104472
crossref_primary_10_1007_s12672_023_00830_z
crossref_primary_10_3389_fonc_2024_1445526
crossref_primary_10_3389_fimmu_2023_1117585
crossref_primary_10_1111_hel_12999
crossref_primary_10_3390_cells10112940
crossref_primary_10_1155_2023_5437526
crossref_primary_10_3390_cancers15123136
crossref_primary_10_1172_jci_insight_168517
crossref_primary_10_1186_s12935_022_02471_8
crossref_primary_10_3390_cancers16132455
crossref_primary_10_3390_molecules28083356
crossref_primary_10_3389_fonc_2023_1168454
crossref_primary_10_1186_s12943_023_01751_9
crossref_primary_10_3389_fimmu_2024_1407995
crossref_primary_10_31083_j_fbl2809206
crossref_primary_10_1136_jitc_2024_010782
crossref_primary_10_1186_s40001_024_02182_y
crossref_primary_10_3389_fimmu_2024_1489827
crossref_primary_10_32604_or_2024_057472
crossref_primary_10_1186_s12967_024_05462_7
crossref_primary_10_1159_000541881
crossref_primary_10_3390_cells13090725
crossref_primary_10_17650_2313_805X_2024_11_3_79_91
crossref_primary_10_3389_fonc_2022_1091383
crossref_primary_10_1038_s41598_023_32375_0
crossref_primary_10_1186_s12943_023_01826_7
crossref_primary_10_1002_wrna_1822
crossref_primary_10_2174_1871527322666230406094257
crossref_primary_10_3390_biology13050307
crossref_primary_10_1136_jitc_2024_009110
crossref_primary_10_3389_fonc_2023_1253418
crossref_primary_10_1186_s12967_024_05689_4
crossref_primary_10_2174_0929867329666220819115849
crossref_primary_10_1038_s41598_022_26000_9
crossref_primary_10_2147_IJGM_S395553
crossref_primary_10_3389_fimmu_2024_1472626
crossref_primary_10_1038_s41467_024_46735_5
crossref_primary_10_3389_fimmu_2024_1411300
crossref_primary_10_3389_fimmu_2025_1560383
crossref_primary_10_3390_cancers16020281
crossref_primary_10_1007_s10565_023_09830_9
crossref_primary_10_1186_s12943_023_01818_7
crossref_primary_10_1007_s10495_024_02022_8
crossref_primary_10_1186_s12967_024_05576_y
crossref_primary_10_3389_fonc_2022_1054458
crossref_primary_10_1007_s10517_023_05972_2
crossref_primary_10_1002_cncr_34729
crossref_primary_10_3389_fimmu_2022_1026076
crossref_primary_10_1136_jitc_2024_009741
crossref_primary_10_18632_aging_204645
crossref_primary_10_3389_fimmu_2023_1135489
crossref_primary_10_3389_fimmu_2023_1163136
crossref_primary_10_1158_2767_9764_CRC_23_0538
crossref_primary_10_3389_fimmu_2025_1544882
crossref_primary_10_1155_ijog_6681711
crossref_primary_10_1126_scitranslmed_adf6732
crossref_primary_10_1038_s41598_022_13101_8
Cites_doi 10.1038/nature14292
10.1242/jcs.02470
10.3390/cancers12092659
10.1038/cr.2017.90
10.1016/j.stem.2021.04.011
10.1016/j.trecan.2018.03.010
10.4049/jimmunol.173.4.2500
10.1056/NEJMoa1003466
10.1038/s41598-019-42303-w
10.3390/cancers13061359
10.2519/jospt.2018.7476
10.1038/s41419-020-2252-3
10.1038/s41591-020-0821-8
10.3390/jcm8081158
10.1007/BF03239969
10.1111/j.1365-2567.2007.02723.x
10.1007/s13277-016-5386-2
10.1056/NEJMoa1200690
10.1186/s40425-019-0816-5
10.2147/OTT.S85272
10.7150/ijbs.41105
10.1080/2162402X.2018.1512943
10.3892/ol.2015.3611
10.1158/1078-0432.CCR-20-2487
10.1016/j.wneu.2019.10.044
10.3892/br.2018.1077
10.1038/nri2326
10.1042/bj0241560
10.1016/j.molmed.2009.03.003
10.1080/2162402X.2020.1748991
10.1038/modpathol.2010.95
10.7150/thno.18217
10.2174/1568026619666190308131805
10.1146/annurev-biophys-083012-130338
10.1073/pnas.0405025101
10.4161/jkst.29510
10.1038/s41419-019-1549-6
10.1002/cti2.1137
10.1158/1078-0432.Ccr-12-0715
10.1158/1078-0432.CCR-17-2852
10.1038/leu.2017.225
10.1038/ni967
10.3390/ijms21197050
10.1111/pcmr.12599
10.1073/pnas.0405259101
10.1007/s00262-020-02771-w
10.1002/ijc.29210
10.1523/JNEUROSCI.20-08-02825.2000
10.1007/s10544-019-0442-5
10.1038/s41423-019-0305-2
10.1038/s41392-020-00280-x
10.1016/j.intimp.2020.106584
10.1016/j.smim.2017.07.011
10.1038/s41392-021-00505-7
10.1073/pnas.0805458105
10.1016/j.jamcollsurg.2019.08.388
10.1056/NEJMoa1200694
10.1158/1538-7445.AM2018-820
10.3892/ol.2017.7142
10.1016/j.cell.2011.02.013
10.4049/jimmunol.168.12.6294
10.1016/j.ebiom.2019.08.030
10.1002/jso.26305
10.1155/2010/683875
10.1038/85339
10.1007/s12013-021-00975-0
10.1158/0008-5472.Can-15-1538
10.4049/jimmunol.172.4.2352
10.3892/or.18.3.745
10.7150/thno.43991
10.1074/jbc.M115.679852
10.1158/1535-7163.Mct-11-0072
10.1016/j.cell.2018.09.035
10.18632/oncotarget.17847
10.1007/s12032-014-0162-x
10.1073/pnas.0807700105
10.1016/j.str.2013.03.003
10.1016/j.immuni.2019.12.011
10.18632/oncotarget.6902
10.1097/SLA.0b013e3181f1939d
10.1038/nrd4596
10.1158/1078-0432.CCR-07-1030
10.1158/1078-0432.CCR-18-0432
10.1053/j.seminoncol.2014.08.004
10.18632/oncotarget.8784
10.3389/fphar.2020.01089
10.1158/1078-0432.CCR-15-2428
10.1080/14712598.2021.1862791
10.7150/jca.17759
10.1038/srep27528
10.1007/s00280-017-3508-1
10.21037/jtd.2020.04.41
10.1007/s13277-015-4132-5
10.1056/NEJMoa1504030
10.1007/s00262-018-2138-8
10.1371/journal.pone.0076965
10.1158/1078-0432.CCR-18-2355
10.1007/s12032-014-0903-x
10.18632/oncotarget.9035
10.1007/s00330-019-06189-6
10.3748/wjg.v21.i6.1804
10.1126/science.1160809
10.1038/nri3701
10.1016/j.immuni.2019.12.010
10.1007/s13277-014-2671-9
ContentType Journal Article
Copyright Copyright © 2021 Zhou and Jin.
Copyright © 2021 Zhou and Jin 2021 Zhou and Jin
Copyright_xml – notice: Copyright © 2021 Zhou and Jin.
– notice: Copyright © 2021 Zhou and Jin 2021 Zhou and Jin
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2021.701006
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ: Directory of Open Access Journal (DOAJ)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_6041d55b007b47f59507ba41f7ba0acb
PMC8326801
34349762
10_3389_fimmu_2021_701006
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: National Key Research and Development Program of China
  grantid: no. 2017FYA0205302
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c465t-be75b0b5d3095a029f09a73003bf0cc5cb030bb6d445fa31d9bf62b9168f054a3
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:31:53 EDT 2025
Thu Aug 21 14:00:24 EDT 2025
Sun Aug 24 03:39:02 EDT 2025
Thu Apr 03 07:06:09 EDT 2025
Tue Jul 01 00:53:07 EDT 2025
Thu Apr 24 23:04:26 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords tumor immunology
tumor microenvironment
B7-H3/CD276
cancer immunotherapy
immune checkpoint
Language English
License Copyright © 2021 Zhou and Jin.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c465t-be75b0b5d3095a029f09a73003bf0cc5cb030bb6d445fa31d9bf62b9168f054a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Wenping Ma, Capital Medical University, China; Lisa Sevenich, Georg Speyer Haus, Germany
Edited by: Mingzhu Yin, Central South University, China
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2021.701006
PMID 34349762
PQID 2558451536
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_6041d55b007b47f59507ba41f7ba0acb
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8326801
proquest_miscellaneous_2558451536
pubmed_primary_34349762
crossref_primary_10_3389_fimmu_2021_701006
crossref_citationtrail_10_3389_fimmu_2021_701006
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-07-19
PublicationDateYYYYMMDD 2021-07-19
PublicationDate_xml – month: 07
  year: 2021
  text: 2021-07-19
  day: 19
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2021
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Zou (B9) 2008; 8
Castellanos (B34) 2017; 6
Buki (B64) 2000; 20
Majzner (B38) 2019; 25
Girardi (B61) 2017; 102
White (B103) 2021; 123
Egen (B1) 2020; 52
Lei (B106) 2019; 21
Proctor (B26) 2019; 8
Jiang (B55) 2016; 7
Zhang (B99) 2015; 8
Sun (B10) 2002; 168
Wilson (B32) 2017; 7
Wu (B51) 2014; 31
El Hage (B52) 2021; 13
Yang (B68) 2009; 15
Michelakos (B73) 2021; 21
Wang (B20) 2016; 37
Lupu (B44) 2007; 18
Li (B49) 2014; 31
Kontos (B85) 2019; 229
Flem-Karlsen (B60) 2019; 9
Qi (B59) 2005; 118
Wang (B57) 2020; 11
Bialosky (B105) 2018; 48
Flem-Karlsen (B19) 2018; 4
Ferlay (B31) 2015; 136
Twyman-Saint Victor (B100) 2015; 520
Lu (B67) 2021; 70
Topalian (B76) 2012; 366
Chen (B12) 2013; 8
Varki (B30) 2018; 67
Suh (B42) 2004; 101
Li (B3) 2018; 81
Chapoval (B8) 2001; 2
Niu (B50) 2015; 36
Zhang (B66) 2015; 21
Lu (B78) 2020; 9
Heiden (B70) 2009; 324
Capalbo (B63) 2009; 185
Wang (B29) 2016; 37
Lei (B96) 2021; 27
Nunes-Xavier (B54) 2016; 7
Hu (B22) 2021; 79
Purvis (B21) 2019; 8
Larkin (B97) 2015; 373
Hegde (B102) 2020; 52
Ma (B82) 2016; 7
Hodi (B75) 2010; 363
Theruvath (B92) 2020; 26
Xie (B58) 2016; 6
Napetschnig (B56) 2013; 42
Raible (B62) 2014; 3
Li (B35) 2020; 12
Scribner (B80) 2018; 78
Ahmed (B101) 2015; 290
Vigdorovich (B88) 2013; 21
Loo (B79) 2012; 18
Aung (B40) 2019; 25
Lim (B71) 2016; 76
Watchorn (B83) 1930; 24
Purvis (B15) 2020; 21
MacGregor (B36) 2019; 7
Wang (B39) 2015; 10
Cai (B37) 2020; 17
Suh (B41) 2003; 4
Prasad (B45) 2004; 173
Weidle (B81) 2014; 41
Zang (B25) 2010; 23
Cong (B23) 2017; 14
Yang (B17) 2020; 16
Yonesaka (B24) 2018; 24
Zang (B6) 2007; 13
Tang (B94) 2020; 9
Pollizzi (B5) 2014; 14
Li (B53) 2017; 8
Davis (B84) 2017; 31
Deng (B27) 2020; 135
Lee (B77) 2017; 27
Zhang (B13) 2008; 123
Yang (B93) 2020; 10
Nehama (B91) 2019; 47
Jin (B48) 2020; 5
Picarda (B18) 2016; 22
Brahmer (B74) 2012; 366
Adams (B87) 2015; 14
Flem-Karlsen (B14) 2017; 30
Castriconi (B46) 2004; 101
Sanmamed (B2) 2018; 175
Hanahan (B69) 2011; 144
Hashiguchi (B16) 2008; 105
Loos (B4) 2010; 2010
Li (B28) 2017; 8
Wang (B47) 2021; 28
Tang (B90) 2021; 6
Steinberger (B11) 2004; 172
Vallera (B86) 2020; 12
Hofmeyer (B7) 2008; 105
Liu (B65) 2011; 10
Shi (B72) 2019; 49
Yang (B95) 2020; 11
Chen (B89) 2019; 19
Lupu (B43) 2006; 10
Xu (B98) 2020; 84
Minami (B104) 2019; 29
Arigami (B33) 2010; 252
References_xml – volume: 520
  year: 2015
  ident: B100
  article-title: Radiation and Dual Checkpoint Blockade Activate Non-Redundant Immune Mechanisms in Cancer
  publication-title: Nature
  doi: 10.1038/nature14292
– volume: 118
  year: 2005
  ident: B59
  article-title: MAP Kinase Pathways
  publication-title: J Cell Sci
  doi: 10.1242/jcs.02470
– volume: 12
  start-page: 2659
  year: 2020
  ident: B86
  article-title: Nk-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
  publication-title: Cancers
  doi: 10.3390/cancers12092659
– volume: 27
  year: 2017
  ident: B77
  article-title: Inhibition of the B7-H3 Immune Checkpoint Limits Tumor Growth by Enhancing Cytotoxic Lymphocyte Function
  publication-title: Cell Res
  doi: 10.1038/cr.2017.90
– volume: 28
  start-page: 1
  year: 2021
  ident: B47
  article-title: CD276 Expression Enables Squamous Cell Carcinoma Stem Cells to Evade Immune Surveillance
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2021.04.011
– volume: 4
  year: 2018
  ident: B19
  article-title: B7-H3 in Cancer - Beyond Immune Regulation
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2018.03.010
– volume: 173
  year: 2004
  ident: B45
  article-title: Murine B7-H3 is a Negative Regulator of T Cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.173.4.2500
– volume: 363
  year: 2010
  ident: B75
  article-title: Improved Survival With Ipilimumab in Patients With Metastatic Melanoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1003466
– volume: 9
  start-page: 5839
  year: 2019
  ident: B60
  article-title: P38 MAPK Activation Through B7-H3-Mediated DUSP10 Repression Promotes Chemoresistance
  publication-title: Sci Rep-Uk
  doi: 10.1038/s41598-019-42303-w
– volume: 13
  start-page: 1359
  year: 2021
  ident: B52
  article-title: Combining Mtor Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13061359
– volume: 48
  start-page: 8
  year: 2018
  ident: B105
  article-title: Unraveling the Mechanisms of Manual Therapy: Modeling an Approach
  publication-title: J Orthop Sports Phys Ther
  doi: 10.2519/jospt.2018.7476
– volume: 11
  start-page: 55
  year: 2020
  ident: B57
  article-title: B7-H3 Promotes Colorectal Cancer Angiogenesis Through Activating the NF-Kappa B Pathway to Induce VEGFA Expression
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-020-2252-3
– volume: 26
  year: 2020
  ident: B92
  article-title: Locoregionally Administered B7-H3-Targeted Car T Cells for Treatment of Atypical Teratoid/Rhabdoid Tumors
  publication-title: Nat Med
  doi: 10.1038/s41591-020-0821-8
– volume: 8
  start-page: 1158
  year: 2019
  ident: B21
  article-title: Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis
  publication-title: J Clin Med
  doi: 10.3390/jcm8081158
– volume: 10
  year: 2006
  ident: B43
  article-title: An Orthotopic Colon Cancer Model for Studying the B7-H3 Antitumor Effect In Vivo
  publication-title: J Gastrointest Surg
  doi: 10.1007/BF03239969
– volume: 123
  year: 2008
  ident: B13
  article-title: Soluble CD276 (B7-H3) is Released From Monocytes, Dendritic Cells and Activated T Cells and is Detectable in Normal Human Serum
  publication-title: Immunology
  doi: 10.1111/j.1365-2567.2007.02723.x
– volume: 37
  year: 2016
  ident: B20
  article-title: The Tumor Suppressor miR-124 Inhibits Cell Proliferation and Invasion by Targeting B7-H3 in Osteosarcoma
  publication-title: Tumour Biol
  doi: 10.1007/s13277-016-5386-2
– volume: 366
  year: 2012
  ident: B76
  article-title: Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa1200690
– volume: 7
  start-page: 357
  year: 2019
  ident: B36
  article-title: High Expression of B7-H3 on Stromal Cells Defines Tumor and Stromal Compartments in Epithelial Ovarian Cancer and Is Associated With Limited Immune Activation
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-019-0816-5
– volume: 8
  year: 2015
  ident: B99
  article-title: B7-H3 Silencing by RNAi Inhibits Tumor Progression and Enhances Chemosensitivity in U937 Cells
  publication-title: Oncotargets Ther
  doi: 10.2147/OTT.S85272
– volume: 16
  year: 2020
  ident: B17
  article-title: B7-H3, a Checkpoint Molecule, as a Target for Cancer Immunotherapy
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.41105
– volume: 8
  start-page: e1512943
  year: 2019
  ident: B26
  article-title: Identification of PD-L2, B7-H3 and CTLA-4 Immune Checkpoint Proteins in Genetic Subtypes of Meningioma
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1512943
– volume: 10
  year: 2015
  ident: B39
  article-title: Differential Expression of 2igB7-H3 and 4igB7-H3 in Cancer Cell Lines and Glioma Tissues
  publication-title: Oncol Lett
  doi: 10.3892/ol.2015.3611
– volume: 27
  year: 2021
  ident: B96
  article-title: A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific Car-T Cells in Solid Tumors
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-2487
– volume: 135
  year: 2020
  ident: B27
  article-title: Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma
  publication-title: World Neurosurg
  doi: 10.1016/j.wneu.2019.10.044
– volume: 185
  year: 2009
  ident: B63
  article-title: Survivin As A Novel Target Protein for Reducing the Proliferation of Cancer Cells
  publication-title: Strahlenther Onkol
  doi: 10.3892/br.2018.1077
– volume: 8
  year: 2008
  ident: B9
  article-title: Inhibitory B7-Family Molecules in the Tumour Microenvironment
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri2326
– volume: 24
  year: 1930
  ident: B83
  article-title: Irradiated Ergosterol and Calcium-Free Diet: Effect on Calcium and Phosphorus Metabolism
  publication-title: Biochem J
  doi: 10.1042/bj0241560
– volume: 15
  year: 2009
  ident: B68
  article-title: Apoptosis and Colorectal Cancer: Implications for Therapy
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2009.03.003
– volume: 9
  year: 2020
  ident: B78
  article-title: B7-H3 Inhibits the IFN-gamma-dependent Cytotoxicity of Vgamma9Vdelta2 T Cells Against Colon Cancer Cells
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2020.1748991
– volume: 23
  year: 2010
  ident: B25
  article-title: Tumor Associated Endothelial Expression of B7-H3 Predicts Survival in Ovarian Carcinomas
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2010.95
– volume: 7
  year: 2017
  ident: B32
  article-title: Spectroscopic Photoacoustic Molecular Imaging of Breast Cancer Using a B7-H3-targeted Icg Contrast Agent
  publication-title: Theranostics
  doi: 10.7150/thno.18217
– volume: 19
  year: 2019
  ident: B89
  article-title: Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions
  publication-title: Curr Top Med Chem
  doi: 10.2174/1568026619666190308131805
– volume: 42
  year: 2013
  ident: B56
  article-title: Molecular Basis of NF-kappaB Signaling
  publication-title: Annu Rev Biophys
  doi: 10.1146/annurev-biophys-083012-130338
– volume: 101
  year: 2004
  ident: B46
  article-title: Identification of 4Ig-B7-H3 as a Neuroblastoma-Associated Molecule That Exerts a Protective Role From an NK Cell-Mediated Lysis
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0405025101
– volume: 3
  start-page: e29510
  year: 2014
  ident: B62
  article-title: Effects of JAK2-STAT3 Signaling After Cerebral Insults
  publication-title: JAKSTAT
  doi: 10.4161/jkst.29510
– volume: 49
  year: 2019
  ident: B72
  article-title: B7-H3 Promotes Aerobic Glycolysis and Chemoresistance in Colorectal Cancer Cells by Regulating HK2
  publication-title: Eur J Immunol
  doi: 10.1038/s41419-019-1549-6
– volume: 9
  start-page: e1137
  year: 2020
  ident: B94
  article-title: Bioactivity and Safety of B7-H3-targeted Chimeric Antigen Receptor T Cells Against Anaplastic Meningioma
  publication-title: Clin Trans Immunol
  doi: 10.1002/cti2.1137
– volume: 18
  year: 2012
  ident: B79
  article-title: Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody With Potent Antitumor Activity
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.Ccr-12-0715
– volume: 24
  year: 2018
  ident: B24
  article-title: B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-2852
– volume: 102
  year: 2017
  ident: B61
  article-title: The T-Cell Leukemia Associated Ribosomal Rpl10 R98s Mutation Enhances Jak-Stat Signaling
  publication-title: Haematologica
  doi: 10.1038/leu.2017.225
– volume: 4
  start-page: 899
  year: 2003
  ident: B41
  article-title: The B7 Family Member B7-H3 Preferentially Down-Regulates T Helper Type 1-Mediated Immune Responses
  publication-title: Nat Immunol
  doi: 10.1038/ni967
– volume: 21
  start-page: 7050
  year: 2020
  ident: B15
  article-title: B7-H3 in Medulloblastoma-Derived Exosomes; A Novel Tumorigenic Role
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21197050
– volume: 30
  year: 2017
  ident: B14
  article-title: Immunoregulatory Protein B7-H3 Promotes Growth and Decreases Sensitivity to Therapy in Metastatic Melanoma Cells
  publication-title: Pigm Cell Melanoma R
  doi: 10.1111/pcmr.12599
– volume: 101
  year: 2004
  ident: B42
  article-title: The Immune Regulatory Protein B7-H3 Promotes Osteoblast Differentiation and Bone Mineralization
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0405259101
– volume: 70
  year: 2021
  ident: B67
  article-title: B7-H3 Confers Resistance to Vgamma9Vdelta2 T Cell-Mediated Cytotoxicity in Human Colon Cancer Cells Via the STAT3/ULBP2 Axis
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-020-02771-w
– volume: 136
  year: 2015
  ident: B31
  article-title: Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29210
– volume: 20
  year: 2000
  ident: B64
  article-title: Cytochrome C Release and Caspase Activation in Traumatic Axonal Injury
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.20-08-02825.2000
– volume: 21
  start-page: 94
  year: 2019
  ident: B106
  article-title: Investigation of Uniform Sized Multicellular Spheroids Raised by Microwell Arrays After the Combined Treatment of Electric Field and Anti-Cancer Drug
  publication-title: BioMed Microdevices
  doi: 10.1007/s10544-019-0442-5
– volume: 6
  start-page: 66
  year: 2017
  ident: B34
  article-title: B7-H3 Role in the Immune Landscape of Cancer
  publication-title: Am J Clin Exp Immunol
– volume: 17
  year: 2020
  ident: B37
  article-title: Tumor-Expressed B7-H3 Mediates the Inhibition of Antitumor T-Cell Functions in Ovarian Cancer Insensitive to PD-1 Blockade Therapy
  publication-title: Cell Mol Immunol
  doi: 10.1038/s41423-019-0305-2
– volume: 5
  start-page: 166
  year: 2020
  ident: B48
  article-title: The Updated Landscape of Tumor Microenvironment and Drug Repurposing
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-020-00280-x
– volume: 84
  year: 2020
  ident: B98
  article-title: Blocking PD-1/PD-L1 by an ADCC Enhanced anti-B7-H3/PD-1 Fusion Protein Engages Immune Activation and Cytotoxicity
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2020.106584
– volume: 31
  start-page: 64
  year: 2017
  ident: B84
  article-title: Natural Killer Cells Unleashed: Checkpoint Receptor Blockade and BiKE/TriKE Utilization in NK-mediated Anti-Tumor Immunotherapy
  publication-title: Semin Immunol
  doi: 10.1016/j.smim.2017.07.011
– volume: 6
  start-page: 125
  year: 2021
  ident: B90
  article-title: Administration of B7-H3 Targeted Chimeric Antigen Receptor-T Cells Induce Regression of Glioblastoma
  publication-title: Signal Transduction Targeted Ther
  doi: 10.1038/s41392-021-00505-7
– volume: 105
  year: 2008
  ident: B7
  article-title: The Contrasting Role of B7-H3
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0805458105
– volume: 229
  year: 2019
  ident: B85
  article-title: Il-15/B7-H3 TriKEs-Based Immunotherapy for Pancreatic Ductal Adenocarcinoma
  publication-title: J Am Coll Surgeons
  doi: 10.1016/j.jamcollsurg.2019.08.388
– volume: 366
  year: 2012
  ident: B74
  article-title: Safety and Activity of Anti-PD-L1 Antibody in Patients With Advanced Cancer
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa1200694
– volume: 78
  start-page: 820
  year: 2018
  ident: B80
  article-title: Preclinical Development of MGC018, a Duocarmycin-Based Antibody-Drug Conjugate Targeting B7-H3 for Solid Cancer
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2018-820
– volume: 14
  year: 2017
  ident: B23
  article-title: Expression of CD24 and B7-H3 in Breast Cancer and the Clinical Significance
  publication-title: Oncol Lett
  doi: 10.3892/ol.2017.7142
– volume: 144
  year: 2011
  ident: B69
  article-title: Hallmarks of Cancer: The Next Generation
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 168
  year: 2002
  ident: B10
  article-title: Characterization of Mouse and Human B7-H3 Genes
  publication-title: J Immunol
  doi: 10.4049/jimmunol.168.12.6294
– volume: 47
  start-page: 33
  year: 2019
  ident: B91
  article-title: B7-H3-redirected Chimeric Antigen Receptor T Cells Target Glioblastoma and Neurospheres
  publication-title: Ebiomedicine
  doi: 10.1016/j.ebiom.2019.08.030
– volume: 123
  year: 2021
  ident: B103
  article-title: Adjuvant Therapy Following Induction Therapy and Surgery Improves Survival in N2-Positive Non-Small Cell Lung Cancer
  publication-title: J Surg Oncol
  doi: 10.1002/jso.26305
– volume: 2010
  year: 2010
  ident: B4
  article-title: B7-H3 and Its Role in Antitumor Immunity
  publication-title: Clin Dev Immunol
  doi: 10.1155/2010/683875
– volume: 2
  year: 2001
  ident: B8
  article-title: B7-H3: A Costimulatory Molecule for T Cell Activation and IFN-Gamma Production
  publication-title: Nat Immunol
  doi: 10.1038/85339
– volume: 79
  start-page: 397
  year: 2021
  ident: B22
  article-title: B7-H3, Negatively Regulated by Mir-128, Promotes Colorectal Cancer Cell Proliferation and Migration
  publication-title: Cell Biochem Biophys
  doi: 10.1007/s12013-021-00975-0
– volume: 76
  year: 2016
  ident: B71
  article-title: Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1 Alpha
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.Can-15-1538
– volume: 172
  year: 2004
  ident: B11
  article-title: Molecular Characterization of Human 4Ig-B7-H3, a Member of the B7 Family With Four Ig-like Domains
  publication-title: J Immunol
  doi: 10.4049/jimmunol.172.4.2352
– volume: 18
  year: 2007
  ident: B44
  article-title: Adenoviral B7-H3 Therapy Induces Tumor Specific Immune Responses and Reduces Secondary Metastasis in a Murine Model of Colon Cancer
  publication-title: Oncol Rep
  doi: 10.3892/or.18.3.745
– volume: 10
  year: 2020
  ident: B93
  article-title: Tandem CAR-T Cells Targeting CD70 and B7-H3 Exhibit Potent Preclinical Activity Against Multiple Solid Tumors
  publication-title: Theranostics
  doi: 10.7150/thno.43991
– volume: 290
  year: 2015
  ident: B101
  article-title: Humanized Affinity-Matured Monoclonal Antibody 8h9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M115.679852
– volume: 10
  year: 2011
  ident: B65
  article-title: B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.Mct-11-0072
– volume: 175
  year: 2018
  ident: B2
  article-title: A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
  publication-title: Cell
  doi: 10.1016/j.cell.2018.09.035
– volume: 8
  year: 2017
  ident: B28
  article-title: B7-H3 Promotes Gastric Cancer Cell Migration and Invasion
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.17847
– volume: 31
  year: 2014
  ident: B49
  article-title: EBP50 Inhibits the Migration and Invasion of Human Breast Cancer Cells Via LIMK/Cofilin and the PI3K/Akt/mTOR/MMP Signaling Pathway
  publication-title: Med Oncol
  doi: 10.1007/s12032-014-0162-x
– volume: 105
  year: 2008
  ident: B16
  article-title: Triggering Receptor Expressed on Myeloid Cell-Like Transcript 2 (TLT-2) is a Counter-Receptor for B7-H3 and Enhances T Cell Responses
  publication-title: P Natl Acad Sci USA
  doi: 10.1073/pnas.0807700105
– volume: 21
  year: 2013
  ident: B88
  article-title: Structure and T Cell Inhibition Properties of B7 Family Member
  publication-title: B7-H3 Struct
  doi: 10.1016/j.str.2013.03.003
– volume: 52
  start-page: 17
  year: 2020
  ident: B102
  article-title: Top 10 Challenges in Cancer Immunotherapy
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.12.011
– volume: 7
  year: 2016
  ident: B54
  article-title: Decreased Expression of B7-H3 Reduces the Glycolytic Capacity and Sensitizes Breast Cancer Cells to AKT/mTOR Inhibitors
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.6902
– volume: 252
  year: 2010
  ident: B33
  article-title: B7-H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis
  publication-title: Ann Surg
  doi: 10.1097/SLA.0b013e3181f1939d
– volume: 14
  year: 2015
  ident: B87
  article-title: Big Opportunities for Small Molecules in Immuno-Oncology
  publication-title: Nat Rev Drug Discovery
  doi: 10.1038/nrd4596
– volume: 13
  year: 2007
  ident: B6
  article-title: The B7 Family and Cancer Therapy: Costimulation and Coinhibition
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-1030
– volume: 25
  year: 2019
  ident: B38
  article-title: Car T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-0432
– volume: 41
  year: 2014
  ident: B81
  article-title: Tumor-Antigen-Binding Bispecific Antibodies for Cancer Treatment
  publication-title: Semin Oncol
  doi: 10.1053/j.seminoncol.2014.08.004
– volume: 7
  year: 2016
  ident: B82
  article-title: B7-H3 as a Promising Target for Cytotoxicity T Cell in Human Cancer Therapy
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8784
– volume: 11
  year: 2020
  ident: B95
  article-title: Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2020.01089
– volume: 22
  year: 2016
  ident: B18
  article-title: Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-2428
– volume: 21
  start-page: 587
  year: 2021
  ident: B73
  article-title: B7-H3 Targeted Antibody-Based Immunotherapy of Malignant Diseases
  publication-title: Expert Opin Biol Ther
  doi: 10.1080/14712598.2021.1862791
– volume: 8
  year: 2017
  ident: B53
  article-title: B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells Via the PI3K/Akt/STAT3 Signaling Pathway
  publication-title: J Cancer
  doi: 10.7150/jca.17759
– volume: 6
  start-page: 27528
  year: 2016
  ident: B58
  article-title: Soluble B7-H3 Promotes the Invasion and Metastasis of Pancreatic Carcinoma Cells Through the TLR4/NF-Kappa B Pathway
  publication-title: Sci Rep
  doi: 10.1038/srep27528
– volume: 81
  year: 2018
  ident: B3
  article-title: B7-H3 in Tumors: Friend or Foe for Tumor Immunity
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-017-3508-1
– volume: 12
  year: 2020
  ident: B35
  article-title: Silencing of CD276 Suppresses Lung Cancer Progression by Regulating Integrin Signaling
  publication-title: J Thorac Dis
  doi: 10.21037/jtd.2020.04.41
– volume: 37
  year: 2016
  ident: B29
  article-title: Roles of Coinhibitory Molecules B7-H3 and B7-H4 in Esophageal Squamous Cell Carcinoma
  publication-title: Tumour Biol
  doi: 10.1007/s13277-015-4132-5
– volume: 373
  start-page: 23
  year: 2015
  ident: B97
  article-title: Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa1504030
– volume: 67
  year: 2018
  ident: B30
  article-title: Pd-L1, B7-H3, and PD-1 Expression in Immunocompetent vs. Immunosuppressed Patients With Cutaneous Squamous Cell Carcinoma
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-018-2138-8
– volume: 8
  start-page: e76965
  year: 2013
  ident: B12
  article-title: Characterization of a Soluble B7-H3 (sB7-H3) Spliced From the Intron and Analysis of sB7-H3 in the Sera of Patients With Hepatocellular Carcinoma
  publication-title: PloS One
  doi: 10.1371/journal.pone.0076965
– volume: 25
  year: 2019
  ident: B40
  article-title: B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates With Locally Aggressive Primary Tumor Features and Increased Vascular Density
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-2355
– volume: 31
  start-page: 1
  year: 2014
  ident: B51
  article-title: Her3 is Associated With Poor Survival of Gastric Adenocarcinoma: Her3 Promotes Proliferation, Survival and Migration of Human Gastric Cancer Mediated by PI3K/AKT Signaling Pathway
  publication-title: Med Oncol
  doi: 10.1007/s12032-014-0903-x
– volume: 7
  year: 2016
  ident: B55
  article-title: The Co-Stimulatory Molecule B7-H3 Promotes the Epithelial-Mesenchymal Transition in Colorectal Cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.9035
– volume: 29
  year: 2019
  ident: B104
  article-title: Radiofrequency Ablation of Liver Metastasis: Potential Impact on Immune Checkpoint Inhibitor Therapy
  publication-title: Eur Radiol
  doi: 10.1007/s00330-019-06189-6
– volume: 21
  year: 2015
  ident: B66
  article-title: Overexpression of B7-H3 Augments Anti-Apoptosis of Colorectal Cancer Cells by Jak2-STAT3
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v21.i6.1804
– volume: 324
  year: 2009
  ident: B70
  article-title: Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
  publication-title: Science
  doi: 10.1126/science.1160809
– volume: 14
  year: 2014
  ident: B5
  article-title: Integrating Canonical and Metabolic Signalling Programmes in the Regulation of T Cell Responses
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3701
– volume: 52
  start-page: 36
  year: 2020
  ident: B1
  article-title: Human Anti-Tumor Immunity: Insights From Immunotherapy Clinical Trials
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.12.010
– volume: 36
  year: 2015
  ident: B50
  article-title: RNA Interference-Mediated Knockdown of RhoGDI2 Induces the Migration and Invasion of Human Lung Cancer A549 Cells Via Activating the PI3K/Akt Pathway
  publication-title: Tumour Biol
  doi: 10.1007/s13277-014-2671-9
SSID ssj0000493335
Score 2.6425438
SecondaryResourceType review_article
Snippet Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 701006
SubjectTerms Animals
B7 Antigens
B7-H3/CD276
cancer immunotherapy
Humans
immune checkpoint
Immunology
Immunotherapy - methods
Neoplasms
tumor immunology
Tumor Microenvironment
SummonAdditionalLinks – databaseName: DOAJ: Directory of Open Access Journal (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA4iCF7Et-uLCp6Eumnz2nrTVVkFPSl4C5k2QUWr6O7Bf-9MU5ddEb14KbRNSfpNkvkmycwwti8L54DcPpQoIZWAQwry4FNfOaVlD4xvHIWvrvXgVl7eqbuJVF90JiyGB47AdTWXWaUU9g4D0gRVIIEBJ7OAV-5KoNkXdd6EMfUYea8QQsVtTLTCim54eH4eoT2YZ4cGbRDKcDShiJp4_T-RzO9nJSeUz_kiW2hZY3IcW7vEZny9zOZiHsmPFZaemHQguv3T3Oij5LhOaKmJsg8lfRLqW3JBXiCtr9XHKrs9P7vpD9I2D0JaSq2GKXiD_w-qEsiHHM-LwAtHceYFBF6WqgQcqQC6klIFJ7KqgKBzQOLXC8jInFhjs_VL7TdYgjd5CICCE0FW3gFCqw03XoEveOAdxr9AsWUbJJxyVTxZNBYIR9vgaAlHG3HssIPxJ68xQsZvhU8I6XFBCm7dPECR21bk9i-Rd9jel5wsDgba4XC1fxm9W7SPehIZmsCK1qPcxlUJKSRyr7zDzJREp9oy_aZ-uG8CbuOsp1GTb_5H47fYPOFBy8NZsc1mh28jv4O8Zgi7TRf-BLv39Gw
  priority: 102
  providerName: Directory of Open Access Journals
Title B7-H3/CD276: An Emerging Cancer Immunotherapy
URI https://www.ncbi.nlm.nih.gov/pubmed/34349762
https://www.proquest.com/docview/2558451536
https://pubmed.ncbi.nlm.nih.gov/PMC8326801
https://doaj.org/article/6041d55b007b47f59507ba41f7ba0acb
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED9NQ6C9IMZnYZsyiSekbE781SBN01bYCtJ4olLfLF9iw9CWQtdK9L_nLkmrFRVeLCWxY-fO5_udnbsDeKsK75HdPrQsMVVIIoV5DGmovDaqjzY0jsJXX8xwpD6P9XgLlumtOgLebTTtOJ_UaHpz9PvX4pQE_oQtTtK3x_H69nZOpl6eHVkyLzgA9wNSTJYTGlx1aP9HC4allLo929zccgceSSUV6eh8TVE18fw3gdC__6W8p5wunsDjDlUmZ-002IWtUD-Fh22eycUzSM9tOpTHgw-5Ne-TszrhrSjOTpQMmOnT5BN7iXS-WIvnMLr4-HUwTLs8CWmpjJ6lGKxGgbqShJe8yIsoCs9x6CVGUZa6RJJkRFMppaOXWVVgNDkSMOxHQmxevoDtelKHV5DQRR4jEmNlVFXwWGltrLBBYyhEFD0QS6K4sgsizrksbhwZE0xS15DUMUldS9IevFs1-dlG0Phf5XOm9KoiB79ubkym31wnS84IldG4aMGwqGzUBWFa9CqLVApfYg8Ol3xyJCx8AuLrMJnfObKf-ooQnKSOXrZ8W3W15HsP7BpH18ay_qS-_t4E5KZV0ZCmf_3Pd76BHf5I3hPOij3Ynk3nYZ_AzAwPmk0AKi_H2UEzXf8AboTxmg
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=B7-H3%2FCD276%3A+An+Emerging+Cancer+Immunotherapy&rft.jtitle=Frontiers+in+immunology&rft.au=Zhou%2C+Wu-Tong&rft.au=Jin%2C+Wei-Lin&rft.date=2021-07-19&rft.eissn=1664-3224&rft.volume=12&rft.spage=701006&rft_id=info:doi/10.3389%2Ffimmu.2021.701006&rft_id=info%3Apmid%2F34349762&rft.externalDocID=34349762
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon